Michael E. Field
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael E. Field has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Michael R. Gold
Medical University of South Carolina
5 shared publications Laura Goldstein
Johnson & Johnson Medical Devices, Franchise Health Economics and Market Access Irvine California USA
4 shared publications- Rahul Khanna
MedTech Epidemiology & Real-World Data Science, Johnson & Johnson, New Brunswick, NJ 08933, USA
3 shared publications - Jonathan P. Piccini
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC (J.P.P.).
2 shared publications Kevin Corriveau
Johnson & Johnson Medical Devices, Franchise Health Economics and Market Access Irvine California USA
2 shared publicationsMichael R. Gold
Medical University of South Carolina, Charleston, South Carolina
2 shared publications
Latest Publications
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Su1760 BULK RNA-SEQUENCING OF BLOOD INFORMS MOLECULAR DIAGNOSES IN VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Su1760 BULK RNA-SEQUENCING OF BLOOD INFORMS MOLECULAR DIAGNOSES IN VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE
- 23 February 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (4) , 831-832
Readmission after atrial fibrillation ablation—Can we prevent the “bounce back”?
- 23 February 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (4) , 831-832
Readmission after atrial fibrillation ablation—Can we prevent the “bounce back”?
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (9) , 595-608
Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study
Background: The accuracy of noninvasive arrhythmia source localization using a forward-solution computational mapping system has not yet been evaluated in blinded, multicenter analysis. This study tested the hypothesis that a computational mapping system incorporating a comprehensive arrhythmia simulation library would provide accurate localization of the site-of-origin for atrial and ventricular arrhythmias and pacing using 12-lead ECG data when compared with the gold standard of invasive electrophysiology study and ablation. Methods: The VMAP study (Vectorcardiographic Mapping of Arrhythmogenic Probability) was a blinded, multicenter evaluation with final data analysis performed by an independent core laboratory. Eligible episodes included atrial and ventricular: tachycardia, fibrillation, pacing, premature atrial and ventricular complexes, and orthodromic atrioventricular reentrant tachycardia. Mapping system results were compared with the gold standard site of successful ablation or pacing during electrophysiology study and ablation. Mapping time was assessed from time-stamped logs. Prespecified performance goals were used for statistical comparisons. Results: A total of 255 episodes from 225 patients were enrolled from 4 centers. Regional accuracy for ventricular tachycardia and premature ventricular complexes in patients without significant structural heart disease (n=75, primary end point) was 98.7% (95% CI, 96.0%–100%; P 0 P 0 P 0 <0.70). Median spatial accuracy was 15 mm (n=255, interquartile range, 7–25 mm). The mapping process was completed in a median of 0.8 minutes (interquartile range, 0.4–1.4 minutes). Conclusions: Computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. Spatial accuracy analysis demonstrated clinically actionable results. This rapid, noninvasive mapping technology may facilitate catheter-based and noninvasive targeted arrhythmia therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04559061.
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 15 (9) , 595-608
Forward-Solution Noninvasive Computational Arrhythmia Mapping: The VMAP Study
Background: The accuracy of noninvasive arrhythmia source localization using a forward-solution computational mapping system has not yet been evaluated in blinded, multicenter analysis. This study tested the hypothesis that a computational mapping system incorporating a comprehensive arrhythmia simulation library would provide accurate localization of the site-of-origin for atrial and ventricular arrhythmias and pacing using 12-lead ECG data when compared with the gold standard of invasive electrophysiology study and ablation. Methods: The VMAP study (Vectorcardiographic Mapping of Arrhythmogenic Probability) was a blinded, multicenter evaluation with final data analysis performed by an independent core laboratory. Eligible episodes included atrial and ventricular: tachycardia, fibrillation, pacing, premature atrial and ventricular complexes, and orthodromic atrioventricular reentrant tachycardia. Mapping system results were compared with the gold standard site of successful ablation or pacing during electrophysiology study and ablation. Mapping time was assessed from time-stamped logs. Prespecified performance goals were used for statistical comparisons. Results: A total of 255 episodes from 225 patients were enrolled from 4 centers. Regional accuracy for ventricular tachycardia and premature ventricular complexes in patients without significant structural heart disease (n=75, primary end point) was 98.7% (95% CI, 96.0%–100%; P 0 P 0 P 0 <0.70). Median spatial accuracy was 15 mm (n=255, interquartile range, 7–25 mm). The mapping process was completed in a median of 0.8 minutes (interquartile range, 0.4–1.4 minutes). Conclusions: Computational ECG mapping using a forward-solution approach exceeded prespecified accuracy goals for arrhythmia and pacing localization. Spatial accuracy analysis demonstrated clinically actionable results. This rapid, noninvasive mapping technology may facilitate catheter-based and noninvasive targeted arrhythmia therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04559061.
- 1 May 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (3) , 245-253
Deep learning model to quantify left atrium volume on routine non-contrast chest CT and predict adverse outcomes
- 1 May 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (3) , 245-253
Deep learning model to quantify left atrium volume on routine non-contrast chest CT and predict adverse outcomes
- 24 December 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 33 (3) , 343-344
Intravenous sotalol—A shortcut to success?
- 24 December 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 33 (3) , 343-344
Intravenous sotalol—A shortcut to success?
- 29 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (9) , 2432-2440
Same‐day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database
Background: Catheter ablation (CA) is a common treatment for atrial fibrillation (AF). This study evaluated outcomes of same day discharge (SDD) versus overnight stay (ONS) among AF patients undergoing outpatient CA.Methods: The Optum SES Clinformatics Extended Data Mart database was used to identify patients ≥18 years of age undergoing outpatient CA for AF (2016–2020). Eligible patients were indexed to the date of first CA and classified into SDD and ONS groups based on the length of service. A 1:3 propensity score matching was used to create comparable SDD:ONS samples. The primary safety outcome was CA‐related complications within 30 days of index procedure. The primary efficacy outcome was AF recurrence within 1 year. Cox proportional hazards models were estimated for outcome comparison.Results: In the postmatch 30‐day cohort for safety evaluation, there were 6600 patients (1660 [25.2%] SDD; 4940 [74.8%] ONS), with a mean age of 66.6 years. There was no significant difference in the 30‐day composite rate of postablation complications (4.7% [78/1660] vs. 3.8% [187/4940];p = 0.100) and 1‐year composite rate of AF recurrence (14.3% [142/996] vs. 14.5% [430/2972];p = 0.705) between the SDD and ONS groups.Conclusion: This study demonstrated that SDD following CA to treat patients with AF is safe, with low rates of postablation complications and AF recurrence, which were comparable to rates in patients with an ONS after CA.
- 29 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (9) , 2432-2440
Same‐day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database
Background: Catheter ablation (CA) is a common treatment for atrial fibrillation (AF). This study evaluated outcomes of same day discharge (SDD) versus overnight stay (ONS) among AF patients undergoing outpatient CA.Methods: The Optum SES Clinformatics Extended Data Mart database was used to identify patients ≥18 years of age undergoing outpatient CA for AF (2016–2020). Eligible patients were indexed to the date of first CA and classified into SDD and ONS groups based on the length of service. A 1:3 propensity score matching was used to create comparable SDD:ONS samples. The primary safety outcome was CA‐related complications within 30 days of index procedure. The primary efficacy outcome was AF recurrence within 1 year. Cox proportional hazards models were estimated for outcome comparison.Results: In the postmatch 30‐day cohort for safety evaluation, there were 6600 patients (1660 [25.2%] SDD; 4940 [74.8%] ONS), with a mean age of 66.6 years. There was no significant difference in the 30‐day composite rate of postablation complications (4.7% [78/1660] vs. 3.8% [187/4940];p = 0.100) and 1‐year composite rate of AF recurrence (14.3% [142/996] vs. 14.5% [430/2972];p = 0.705) between the SDD and ONS groups.Conclusion: This study demonstrated that SDD following CA to treat patients with AF is safe, with low rates of postablation complications and AF recurrence, which were comparable to rates in patients with an ONS after CA.
- Open Access
- 14 July 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (4) , 333-340
Evaluating outcomes of same-day discharge after catheter ablation for atrial fibrillation in a real-world cohort
- 14 July 2021
- Published by Elsevier in Heart Rhythm O2
- Vol. 2 (4) , 333-340
Open AccessEvaluating outcomes of same-day discharge after catheter ablation for atrial fibrillation in a real-world cohort
- 10 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (9) , 2498-2503
Electrical delays in quadripolar leads with cardiac resynchronization therapy
Background: Pacing at sites of late intraventricular activation (QLV) or long interventricular conduction (right ventricle [RV]‐left ventricular [LV]) have been associated with improved cardiac resynchronization therapy (CRT) outcomes. Quadripolar leads improve CRT outcomes by allowing for electrical repositioning to optimize pacing sites. However, little is known regarding the effect of such repositioning on electrical delay.Objective: Determine the relationship between different electrical bipoles from a quadripolar lead and measures of electrical delay.Methods: Forty‐six patients underwent CRT with a quadripolar lead. The RV‐LV and QLV intervals were measured for both the proximal and distal bipoles and the difference (Δ) between bipoles for each measure were calculated. Multivariate analyses were performed to identify predictors of electrical delays.Results: This was a typical CRT population with a mean age of 65 years and ejection fraction of 27%, with left bundle branch block (LBBB) present in 70%. The regression model for ΔQLV was significant (p = .05), with both gender (p = .008) and LBBB status (p = .020) significant predictors. The overall regression model for ΔRV‐LV was not significant. ΔQLV and ΔRV‐LV were significant among LBBB patients. Among non‐LBBB, only ΔRV‐LV was significant (mean: 7.2 ms, p = .006). ΔRV‐LV versus ΔQLV were strongly correlated in LBBB (R2 = .92) but not non‐LBBB (R2 = .06).Conclusion: In LBBB, ΔRV‐LV and ΔQLV are closely correlated suggesting that the proximal bipole and thus basal LV pacing sites should be selected when feasible. Greater variation in activation pattern is present in non‐LBBB, so pacing sites should be individualized.
- 10 July 2021
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 32 (9) , 2498-2503
Electrical delays in quadripolar leads with cardiac resynchronization therapy
Background: Pacing at sites of late intraventricular activation (QLV) or long interventricular conduction (right ventricle [RV]‐left ventricular [LV]) have been associated with improved cardiac resynchronization therapy (CRT) outcomes. Quadripolar leads improve CRT outcomes by allowing for electrical repositioning to optimize pacing sites. However, little is known regarding the effect of such repositioning on electrical delay.Objective: Determine the relationship between different electrical bipoles from a quadripolar lead and measures of electrical delay.Methods: Forty‐six patients underwent CRT with a quadripolar lead. The RV‐LV and QLV intervals were measured for both the proximal and distal bipoles and the difference (Δ) between bipoles for each measure were calculated. Multivariate analyses were performed to identify predictors of electrical delays.Results: This was a typical CRT population with a mean age of 65 years and ejection fraction of 27%, with left bundle branch block (LBBB) present in 70%. The regression model for ΔQLV was significant (p = .05), with both gender (p = .008) and LBBB status (p = .020) significant predictors. The overall regression model for ΔRV‐LV was not significant. ΔQLV and ΔRV‐LV were significant among LBBB patients. Among non‐LBBB, only ΔRV‐LV was significant (mean: 7.2 ms, p = .006). ΔRV‐LV versus ΔQLV were strongly correlated in LBBB (R2 = .92) but not non‐LBBB (R2 = .06).Conclusion: In LBBB, ΔRV‐LV and ΔQLV are closely correlated suggesting that the proximal bipole and thus basal LV pacing sites should be selected when feasible. Greater variation in activation pattern is present in non‐LBBB, so pacing sites should be individualized.
- 1 February 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (2) , 128-137
Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines–Atrial Fibrillation Registry
Background - Antiarrhythmic drug (AAD) therapy for atrial fibrillation (AF) can be associated with both proarrhythmic and noncardiovascular toxicities. Practice guidelines recommend tailored AAD therapy for AF based on patient-specific characteristics, such as coronary artery disease and heart failure, to minimize adverse events. However, current prescription patterns for specific AADs and the degree to which these guidelines are followed in practice are unknown. Methods - Patients enrolled in the Get With The Guidelines-AFIB registry with a primary diagnosis of AF discharged on an AAD between 1/2014 and 11/2018 were included. We analyzed rates of prescription of each AAD in several subgroups including those without structural heart disease. We classified AAD use as guideline-concordant or non-guideline concordant based on six criteria derived from the AHA/ACC/HRS AF Guidelines. Guideline concordance for amiodarone was not considered applicable, since its use is not specifically contraindicated in the guidelines for reasons such as structural heart disease or renal function. We analyzed guideline-concordant AAD use by specific patient and hospital characteristics, and regional and temporal trends. Results - Among 21,921 patients from 123 sites, the median age was 69 years, 46% female, and 51% had paroxysmal AF. The most commonly prescribed AAD was amiodarone (38%). Sotalol (23.2%) and dofetilide (19.2%) were each more commonly prescribed than either flecainide (9.8%) or propafenone (4.8%). Overall guideline-concordant AAD prescription at discharge was 84%. Guideline-concordant AAD use by drug was as follows: dofetilide 93%, sotalol 66%, flecainide 68%, propafenone 48%, and dronedarone 80%. There was variability in rate of guideline-concordant AAD use by hospital and geographic region. Conclusions - Amiodarone remains the most commonly prescribed AAD for AF followed by sotalol and dofetilide. Rates of guideline-concordant AAD use were high and there was significant variability by specific drugs, hospitals, and regions, highlighting opportunities for additional quality improvement.
- 1 February 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (2) , 128-137
Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines–Atrial Fibrillation Registry
Background - Antiarrhythmic drug (AAD) therapy for atrial fibrillation (AF) can be associated with both proarrhythmic and noncardiovascular toxicities. Practice guidelines recommend tailored AAD therapy for AF based on patient-specific characteristics, such as coronary artery disease and heart failure, to minimize adverse events. However, current prescription patterns for specific AADs and the degree to which these guidelines are followed in practice are unknown. Methods - Patients enrolled in the Get With The Guidelines-AFIB registry with a primary diagnosis of AF discharged on an AAD between 1/2014 and 11/2018 were included. We analyzed rates of prescription of each AAD in several subgroups including those without structural heart disease. We classified AAD use as guideline-concordant or non-guideline concordant based on six criteria derived from the AHA/ACC/HRS AF Guidelines. Guideline concordance for amiodarone was not considered applicable, since its use is not specifically contraindicated in the guidelines for reasons such as structural heart disease or renal function. We analyzed guideline-concordant AAD use by specific patient and hospital characteristics, and regional and temporal trends. Results - Among 21,921 patients from 123 sites, the median age was 69 years, 46% female, and 51% had paroxysmal AF. The most commonly prescribed AAD was amiodarone (38%). Sotalol (23.2%) and dofetilide (19.2%) were each more commonly prescribed than either flecainide (9.8%) or propafenone (4.8%). Overall guideline-concordant AAD prescription at discharge was 84%. Guideline-concordant AAD use by drug was as follows: dofetilide 93%, sotalol 66%, flecainide 68%, propafenone 48%, and dronedarone 80%. There was variability in rate of guideline-concordant AAD use by hospital and geographic region. Conclusions - Amiodarone remains the most commonly prescribed AAD for AF followed by sotalol and dofetilide. Rates of guideline-concordant AAD use were high and there was significant variability by specific drugs, hospitals, and regions, highlighting opportunities for additional quality improvement.
- Open Access
- 6 October 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (12) , 3166-3175
Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation
Background: Catheter ablation is an effective treatment for patients with atrial fibrillation (AF) and heart failure (HF). However, little is known about how healthcare utilization and cost change after ablation in this population. We sought to determine healthcare utilization and cost patterns among patients with AF and HF undergoing ablation.Methods: Using a large United States administrative database, we identified (n = 1568) treated with ablation with a primary and secondary diagnosis of AF and HF, respectively, were evaluated 1‐year pre‐ and postablation for outcomes including inpatient admissions (AF or HF), emergency department (ED) visits, cardioversions, length of stay (LOS), and cost. A secondary analysis was extended to 3‐years postablation.Results: Reductions were observed in AF‐related admissions (64%), LOS (65%), cardioversions (52%), ED visits (51%, all values, p < .0001), and HF‐related admissions (22%, p = .01). There was a 40% reduction in inpatient admission cost ($4165 preablation to $2510 postablation, p < .0001). In a sensitivity analysis excluding repeat‐ablation patients, a greater reduction in overall AF management cost was observed compared to the full cohort (−43% vs. −2%). Comparing 1‐year pre‐ to 3‐years postablation, both total mean AF‐management cost ($850 per‐patient per‐month 1‐year pre‐ to $546 3‐years postablation, p < .0001) and AF‐related healthcare utilization was reduced.Conclusions: Catheter ablation in patients with AF and HF resulted in significant reductions in healthcare utilization and cost through 3‐years of follow‐up. This reduction was observed regardless of whether repeat ablation was performed, reflecting the positive impact of ablation on longer term cost reduction.
- 6 October 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (12) , 3166-3175
Open AccessHealthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation
Background: Catheter ablation is an effective treatment for patients with atrial fibrillation (AF) and heart failure (HF). However, little is known about how healthcare utilization and cost change after ablation in this population. We sought to determine healthcare utilization and cost patterns among patients with AF and HF undergoing ablation.Methods: Using a large United States administrative database, we identified (n = 1568) treated with ablation with a primary and secondary diagnosis of AF and HF, respectively, were evaluated 1‐year pre‐ and postablation for outcomes including inpatient admissions (AF or HF), emergency department (ED) visits, cardioversions, length of stay (LOS), and cost. A secondary analysis was extended to 3‐years postablation.Results: Reductions were observed in AF‐related admissions (64%), LOS (65%), cardioversions (52%), ED visits (51%, all values, p < .0001), and HF‐related admissions (22%, p = .01). There was a 40% reduction in inpatient admission cost ($4165 preablation to $2510 postablation, p < .0001). In a sensitivity analysis excluding repeat‐ablation patients, a greater reduction in overall AF management cost was observed compared to the full cohort (−43% vs. −2%). Comparing 1‐year pre‐ to 3‐years postablation, both total mean AF‐management cost ($850 per‐patient per‐month 1‐year pre‐ to $546 3‐years postablation, p < .0001) and AF‐related healthcare utilization was reduced.Conclusions: Catheter ablation in patients with AF and HF resulted in significant reductions in healthcare utilization and cost through 3‐years of follow‐up. This reduction was observed regardless of whether repeat ablation was performed, reflecting the positive impact of ablation on longer term cost reduction.